Deep ResearchBuyer GuideNovember 23, 2026 · 28 min read · VEMERIX

How to Verify Disposable Circumcision Devices Before Placing an Order (2026)

A procurement workpaper for matching disposable circumcision device samples to registrations, sterile-lot evidence and purchase-order terms.

Sterile packaging and inspection materials on a procurement quality workstation

1. Match the sample to the order decision

Consider a distributor preparing a trial purchase of two sizes of disposable circumcision device for one destination. There are two labeled samples, a sales quote and a quality system certificate. The sample can show how the commercial packaging is opened and allow trained staff to assess defined acceptance checks under the applicable supplier specification. The team still needs device-level evidence for the intended market and a way to select, identify and release the production lot.

The first request is a single row per model and size, or an equivalent controlled record. Ask for the exact legal manufacturer and manufacturing site, the named device and model, size range and applicable IFU, the device-level certificate or applicable exemption or filing basis, the case quantity, and the labelling and identifier at each package level. Record which entity is the seller, contract manufacturer, sterilizer, importer and responsible regulatory party. Names can reasonably differ across records when their roles and authorizations link correctly. Trace the actual offered product through these roles before approving the purchase specification 4 5 6.

For an existing catalogue item, the initial diligence answer is a traceable commercial sample from the relevant revision and a credible manufacturing and release chain. For a proposed private label, new size or package combination, classify the change and determine what approvals or validation the supplier will need before producing the new version. The buyer can approve engineering samples for their limited purpose while keeping order authorization conditional on the production version and its regulatory documentation. Separate supplier statements from objective approval records, and keep the sample test and lot release as separate sign-offs.

Review post-market cases by product and mechanism

Use FDA’s classification and recall tools to identify relevant cases, then open the actual recall and classification records. Keep separate entries for the product, recall number and event, and for any single event affecting more than one marketed configuration. A lot of sterile kits recalled after a problem in release is a reminder to link the sterilization load and disposition to the ship lot. A recall can cover finished trays that contain a separately supplied item, as the FDA record Z-2546-2026 shows 7. Tie the sourcing requirement to the failure mechanism. Do not apply a ratio from records to the probability for a supplier or design 1 2 3.

Use named recalls and prompts to check kit traceability
EvidenceWhat it can establishBuyer review question
Actual FDA sterilization recall Z-1824-2026A specific kit lot was distributed without its required sterilization processCan the proposed supplier trace each finished lot to its own release evidence?
Actual FDA record Z-2546-2026A separately supplied item can affect several listed finished kitsCan the buyer and supplier identify the applicable affected kit and component lots?
Proposed additional checkA pack and case can have different identifiersCan actual receiving match both levels to the correct size and lot?

Use specific notices to test a failure pathway; their existence gives no comparative supplier failure rate.

Source: FDA Z-1824-2026, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/res.cfm?ID=219261; FDA Z-2546-2026, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=221020.

2. Market documentation follows the exact device

A search of regulation or registration databases can produce a superficially similar clamp, ring or stapler. Compare intended use, design, intended population, manufacturing site and package configuration before using the evidence. Identify the exact destination and confirm the local holder or representative and importer can perform their roles. A generic classification or registration record is a starting point for the dossier review 8 9 10.

Authorization review by destination
DestinationApplicable assessmentEvidence to reconcile
United StatesClassify the exact device and resolve the applicable market routeIntended use, model, relevant decision or exemption, listing and importer role
EEACheck risk classification, assessment route and any Article 120 relianceDeclaration, certificate where required, authorization conditions and identification
ChinaIdentify local registration and manufacturing requirements for the offered SKUActual certificate status, listed model and size, manufacturing site and validated pack

Verify the offered variant against the applicable destination record and label.

Source: China Order 739, Articles 13–14 and 22, https://app.www.gov.cn/govdata/gov/202103/18/469502/article.html; U.S. FDA product classification OHG, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=OHG, and 510(k) database, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm; EU MDR, including Article 120, https://eur-lex.europa.eu/eli/reg/2017/745/oj.

For a Chinese registration, have the supplier provide the certificate, permitted model/size schedule, applicable product technical requirements and the date and status from the regulator. Confirm any site and manufacturing licence dependencies. An identifier with a year in it is a record locator. Actual validity comes from the certificate, relevant regulator record, applicable rules and any changes 8 11.

For the United States, check the applicable device classification and basis for marketing, including the precise exemption conditions, if relied upon, or a device-specific decision and labelling. A product code alone leaves regulatory scope, product design, and the decision about the marketed indication unresolved. The reclassification order for specified surgical staplers applies to the devices it covers, and requires a product-specific applicability assessment 9 10 12. An FDA establishment registration and device listing must be checked in their own roles and do not confer clearance or approval 6.

For the EEA, obtain the classification rationale for the exact intended use and mode and duration of contact, identify the applicable conformity-assessment route, and reconcile the legal manufacturer, declaration of conformity, the certificate where applicable, the linked documentation and the variant offered. Screen EUDAMED availability against the applicable modules, date and device-level transition. A sterile procedure pack can raise different questions from the standalone instrument. Obtain a separate documented assessment for other destinations, including Great Britain or Northern Ireland where relevant 5 13 14.

3. The Six-Gate Sample-to-Purchase-Order Stop-Order Framework

Track three separate milestones. Qualification determines whether the buyer can use the supplier and sample evidence for the proposed item. A development or production authorization signs off the commercial or engineering work it can initiate. Shipment release applies to actual clinical stock and requires the applicable final market, specification and lot evidence. For an already validated catalogue item, a purchaser can require a traceable commercial sample and verified product documents before an order deposit. For private-label development or a new package, a limited tooling authorization can precede product validation under the agreement. Tie it to agreed deliverables, permitted engineering use and review of any changes. An engineering or payment authorization has no effect on what can be supplied for clinical use.

Evidence available at each order decision
MilestoneReview evidencePermitted decisionReason to hold
QualificationCatalogue documents or defined engineering scope; exact role, model, revision and sample traceApprove supplier candidate and limited use of sampleSample cannot be reconciled to proposed item
Development or production authorizationAgreed deliverables, approved specification, change assessment and applicable product evidence at that stageAuthorize defined work subject to unresolved dependenciesProposed size or pack falls outside current evidence
Shipment releaseFinal applicable label, authorization, lot release, traceability and acceptance recordRelease identified, approved clinical stockLot identity or applicable release evidence is missing

The controls illustrate three different buyer authorizations. Determine applicable legal requirements for the exact destination and device.

Source: Proposed buyer controls informed by ISO 13485:2016, https://www.iso.org/standard/59752.html, and applicable EU MDR 2017/745, https://eur-lex.europa.eu/eli/reg/2017/745/oj.

Have regulatory affairs reconcile the purchase specification to its destination. In a signed role-and-authorization record, identify who issues the declaration, who owns the device authorization where applicable, which site manufactures or sterilizes, who performs vigilance, and which legal entity is authorized to supply the model. Where an entity or address differs, request the evidence that links the parties and sites, such as the agreement, certificate scope or documented legitimate change. Resolve discrepancies before supplier approval 8 5 11 6.

For an EU device marketed under Article 120, review the conditions against the certificate and intended configuration. Check whether the certificate or declaration qualifies under the timeline, withdrawal status and relevant class-specific end date. The applicable transitional route requires ongoing compliance with the previous directive, no significant change in design or intended purpose and no unacceptable health or safety risk. Check the May 26, 2024 deadlines for the required quality management system and formal application and the September 26, 2024 notified-body agreement deadline. Where a qualifying certificate expired before March 20, 2023, address the additional agreement or competent-authority conditions explicitly. Check applicable current post-market and registration duties and obtain the documented change assessment for a new size 5 15.

Agree who can reject an unsupported product representation and which documents must be refreshed before the order is accepted. A published brochure, import listing or general QMS certificate can point testers to additional records. Resolve market authorization separately using evidence for the specific item and intended population. If any bundled component might be regulated differently, open a separate classification and authorization line in the bill of materials.

3.2 Gate 2: size, identifier and packaging reconciliation

Prepare an identifier worksheet with one row per offered catalogue size or model. Record the model, manufacturer size designation, IFU version, the applicable device identifier, the package level and the label revision. For an EU device that requires one, the Basic UDI-DI identifies the relevant device group in documentation. The device-level UDI-DI and the applicable package-level identifiers are distinct, and production identifiers carry batch-specific data. Under the applicable EU and U.S. rules, assess whether changes could cause ambiguity or require new identifiers. Check exceptions and device status before assuming every label uses the same rules 5 13 16 14.

Identity check across label levels
RecordField to confirmEvidence
Authorisation or conformityApplicable exact models, sizes, intended use and siteCertificate, determination or other applicable evidence
Unit and outer packDevice and packing level under relevant rulesDocumented scan result, model, quantity and qualified revision
Manufacturing releaseProduction lot and release decisionLot-specific quality record and approved disposition

Use the destination, packaging level and model to resolve each identifier.

Source: EU MDR Article 27 and Annex VI, https://eur-lex.europa.eu/eli/reg/2017/745/oj; MDCG 2018-1 Rev. 4, https://health.ec.europa.eu/system/files/2021-04/md_mdcg_2018-1_guidance_udi-di_en_0.pdf; 21 CFR Part 830, https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-830.

During review, give the warehouse a representative unit, its carton and an order line. Ask receiving to resolve each barcode and label to the approved row, then repeat with a different size packed in a mismatched carton as a negative case. Capture images, decoded data and the expected pack count. Route differences to Quality and Regulatory Affairs. Use the device-specific IFU and documentation for sizing rather than inferring fit or clinical suitability from label colour or diameter alone. Document mismatches before requesting a change, and re-run the trace for the final lot.

3.3 Gate 3: packaging, shipment simulation and expiry evidence

Match the approved sterile-barrier configuration to the offered product and lot. Ask for the applicable ISO 11607-1 material and design evidence and the ISO 11607-2 process validation scope. Check the package design, sealing site, equipment, smallest and largest relevant devices or other justified worst cases, planned shipping configuration, and controls after storage. Where the supplier uses a distribution simulation, verify that it represents the actual package and distribution hazards. The sample and production lot should share the covered packaging and label revision 17 18.

Ask which ageing method supports the claimed labelled expiry, the evidence or ongoing programme for real-time conditions, and how package integrity and the device's relevant functions were evaluated at claimed expiry. The applicable accelerated-ageing protocol is product-dependent. Record the test standard and edition, sample conditioning, test endpoints and any outstanding real-time confirmation. A valid design or release claim needs the tested configuration to match the current one 19.

The buyer should obtain a witnessed or independent sample check using a qualified method for that package or commission a laboratory when qualified testing is unavailable. Keep acceptance limits from the current validation protocol, including the applicable seal tests and acceptance criteria. Visual inspection or qualified tests can identify damage or other defects. QA documents handling and disposition under the approved procedure. The inspection provides limited sample evidence. Continue to verify the routine lot records and validated process. Hold stock for a confirmed breach or unidentified packaging change, and apply the agreed defect disposition procedure 17 18.

3.4 Gate 4: sterilization and lot-specific release evidence

Ask which terminal sterilization process and release method the exact device uses and which manufacturing and sterilization sites, defined load configurations, packages and product families are covered. For an ethylene oxide (EO) route, ISO 11135 addresses the process design, validation and routine control. A supplier operating a validated biological indicator or parametric release approach should show the applicable validation and how its process records are reviewed, including action on an excursion. Review the current requalification status against the programme and whether a process, supplier, configuration, material or site change requires assessment or additional work 20.

Discuss residue evaluation separately. ISO published a new ISO 10993-7 edition in 2026, with EO and ECH residue limits and test conditions tied to patient population and duration of use. Verify which edition and any regulator recognition conditions apply at the destination. Have a qualified reviewer confirm the assessment for the exact patient-contacting components, indicated populations and contact duration, including components that remain after the procedure. Obtain the sampling conditions and resultant margin or justification. An adult limit or an unverified body-weight scaling formula is unsuitable for deciding paediatric lot acceptance 21.

Ask the manufacturer to demonstrate lot segregation and linking, from the pack label and manufacturer production lot to the sterilization lot and release evidence. Obtain the approved lot release result, the sterilizer and cycle/load reference, any qualification and exception dispositions, and the release date and signature. The acceptance condition is evidence from the validated process appropriate to the lot, with authorized exceptions resolved. Match the certificate of sterilization to the site and load named in the actual order. If the site changed mid-contract, retain a record showing how the process and its applicability were assessed before first shipment 4 21 20.

3.5 Gate 5: traceability, complaint handling and vigilance

Request an example of the lot genealogy for an external kit supplier and perform a mock trace from one pack identifier forward to distribution and back to the lot records, including sterile release. Procedure kits should include a controlled BOM that distinguishes components the manufacturer makes from those sourced as released products or supplied by a separate legal manufacturer. When the supplier replaces a kit item, require the change decision and traceability map before the buyer accepts the new configuration. Specific regulatory obligations depend on the markets and roles 4 5 3.

In the U.S., the QMSR took effect on February 2, 2026. The manufacturer maintains complaint review, evaluation and investigation records within the scope of section 820.35(a), with required fields for reportable and specified investigated complaints as defined there. Use the published provision to verify device name, receipt date, identifiers, complainant information, nature and details, any correction or corrective action taken, and any reply. Document the rationale if a similar complaint has already been investigated. Complaint recordkeeping and mandatory reporting under Part 803 are separate. Use the FDA’s role-specific guidance to assign manufacturer, importer and facility events, recipient and filing clocks 22 4 23.

In the EEA, identify reportability, recipient and timing under the applicable MDR vigilance provisions for the responsible manufacturer and economic operators. A WHO-prequalified product can have additional programme reporting and change obligations; check the current applicable WHO programme documents and product scope. Keep a separate written route for a buyer to notify the supplier internally, a regulator reporting decision, and notice to any procurement programme. A purchase agreement should arrange access to pre-change documents and prompt cooperation for a complaint or field action involving any supplied lot 5 24.

3.6 Gate 6 — Commercial Invoice, Tariff Exposure, and Landed-Cost Reconciliation

The buyer’s quote comparison should use the same model, destination, port or named place, order mix, allocation of freight and release evidence. Use the destination’s applicable commodity code system. In the U.S., verify the full HTSUS classification and applicable Chapter 99 provisions with the importer and broker using the actual article, origin, entry date and applicable exclusion. Determine duty for the actual article. Ask for a written entry basis before accepting the modeled duty 25 26.

Comparable quote scenarios to a single U.S. warehouse
Cost fieldQuote AQuote B
Same scope and boundary5,000 units; FCA named export terminal to U.S. warehouseSame
GoodsUSD 89,000USD 84,500
Transport, entry, receiving and agreed QAUSD 11,500USD 11,500
Additional contingency at 1% of goodsUSD 890USD 845
Total before possible duties and excluded costsUSD 101,390, 20.28 per sellable unitUSD 96,845, 19.37 per sellable unit
Assumed additional duty of 25% of goodsUSD 22,250USD 21,125
Total under duty sensitivityUSD 123,640, 24.73 per sellable unitUSD 117,970, 23.59 per sellable unit

Compare the same quantity, destination and costs. The tariff and listed charges are hypothetical inputs.

Source: Hypothetical comparison. Tariff lookup: USITC HTS and Chapter 99, https://hts.usitc.gov/; USTR Section 301 tariff actions and exclusions, https://ustr.gov/issue-areas/enforcement/section-301-investigations/tariff-actions. Verify classification, entry date, origin and applicable exclusions.

Compare two quotes at one delivery boundary

Suppose two suppliers can meet the same purchase specification for 5,000 sellable units of two configurations, through the same U.S. import and warehouse arrangements. Compare from FCA named export terminal through receipt into the buyer’s U.S. warehouse. Seller costs to that boundary are in the quote. Buyer-paid freight and insurance from the named place, entry expenses, inspection and receiving are included below. Any origin, good-specific and other customs charges must be verified before purchase. The demonstration assumes there is no duty under the particular hypothetical inputs. This is a modeled parameter, with an alternate rate used only to stress-test the comparison. Exclude sales tax, financing, clinical distribution and costs already in the quoted amount. Each input is hypothetical and uses the same lot and QA scope.

Quote A is $17.80 per sellable unit (goods $89,000). Quote B is $16.90 (goods $84,500). For both, use $6,000 for onward transport and insurance, $2,000 for entry and receiving services and $3,500 for agreed inspection, qualified destructive tests and retained reference units. The eligible unit denominator is 5,000. As a stipulated contingency line, add 1% of goods cost only, before tariff, freight and checks. A is then $101,390 ($20.28 per unit to nearest cent). B is $96,845 ($19.37). A comparable quotation must separately state terms, fees and what is payable if evidence fails, and the estimates above do not determine actual shipment-release eligibility.

A sensitivity case assigns an additional 25% of goods value solely as an assumed dutiable base, without assuming an actual classification, origin rule or surcharge applies. That raises A by $22,250 to $123,640 ($24.73) and B by $21,125 to $117,970 ($23.59). Review documentation for the actual dutiable value and tariff. Separate a duty sensitivity from a quality incident. Suppose one 500-unit lot needs testing and replacement handling at $15 per affected unit plus $3,000 freight. The hypothetical conditional extra expense would be $10,500. With a supported probability of 10% it would add $1,050 as an expected cost over repeated comparable orders; without such evidence, compare it as a scenario only. Avoid counting an incident line twice if the contingency reserve already covers it. If the actual quote uses a different destination or customs boundary, restate both prices and the permitted options under the same terms 25 26.

Agree the purchasing and payment terms

  • Order, pack and destination. Record SKU, permitted size and device status, applicable unit or package identifiers and their exceptions, quantities and origin. Identify both package and shipment-level counts. Confirm the commodity code in the applicable destination system. Require any extra line-level invoice field as a stated buyer term 5 13 16 25.
  • Condition on arrival. Agree a minimum remaining usable life based on receiving, distribution and use timing, with approved compensation for short dated lots. Specify the measurement point and recall or replacement obligations. Record packaging and transport needs under the actual validated configuration.
  • Inspection quantity. Agree the lot definition, applicable sizes and acceptance and test plans first. Price the units needed for non-destructive inspection, units consumed in each test and independently sealed units needed for retention. Set separate counts for heterogeneous configurations where appropriate and state which stock can be returned to released inventory 17 18 27.
  • Payment events. Define which evidence supports catalogue qualification or engineering authorization, which output allows production or purchase of specified components against an agreed deliverable, and when the buyer can release the balance. The agreement may allow scoped development fees before the final model and labels are established. Shipment release remains subject to final applicable authorization and the agreed acceptance and documented lot release. Request EO-specific process evidence only for the EO route; otherwise review the process and lot documentation applicable to the marketed product 4 5 20.

4. Incoming inspection, lot disposition and release

Specify a homogeneous lot and document how the inspection samples will be drawn across relevant carton positions and offered sizes. QA should identify the current applicable edition of the sampling standard or buyer-approved plan for non-destructive attributes, along with lot size, inspection level, sample size and acceptance/rejection numbers. For destructive checks, use a separate authorized plan tied to the validated product and method. If the buyer sets a zero-acceptance critical-defect policy, label it as buyer policy and record the implications for lot release. Sampling measures the inspected units and bounds an acceptance decision under the plan. Avoid interpreting zero observed defects as an assurance that the lot is defect-free 27.

Use the supplier's verified inspection or functional limits for the exact version, including the allowed measurement method, test medium if relevant, fixture and judged defects. Keep bench acceptance within its authorized scope. Where performance depends on the verified intended population, use the relevant IFU, contraindications and training documentation to confirm the purchasing requirement. Apply the agreed risk classification, with separate disposition for critical defects, significant changes and less serious discrepancies. Inspect the supplier's correction assessment and obtain authorization for any rework or resampling before re-inspection 4 5 27.

A receiving worksheet should identify who placed the hold, the affected cartons and lot, the defect and the exact specification reference, the sample drawn, and whether the approved action is additional investigation, rejection, authorized rework or disposition under an approved concession. Do not release an order if the authorization or sterile-barrier claim remains unsupported. A size label problem should stay associated with its device and pack-level identifier in the supplier report. Confirm the agreed corrective action is reflected in the new release documents and that all prior lot identifiers remain traceable after a correction.

5. Apply the acceptance checks to the exact architecture

  • Stapler or anastomat: Obtain the controlled models, intended sizes and approved test protocol. The applicable inspection can check model-specific mechanical performance, locking, the expected closure and how a nonconformity affects the validated specification. Keep the specified tested specimens and separate unopened reference units when required by the approved plan. A successful sample function test provides evidence for the stated conditions, not regulatory approval or a clinical performance comparison 9 10 12.
  • Ring or ligature device: Review the intended population, sizing method, any follow-up or removal instructions, and appropriate labeled precautions under the exact model’s IFU. Where WHO prequalification is cited, verify the named device and production site and the relevant programme scope 5 24.
  • Clamp: Determine whether the offered lot is sterile and single use, and confirm which policy is applied to inspection of each size and attachment in the marketed configuration. If a different model or intended use is proposed, open a documented change assessment with Quality and Regulatory Affairs before ordering 9 10 4.
  • Tray or procedure kit: Verify the individual sub-tier items, their expiry dates and lot-to-kit linkage, and which entity assembles and releases the finished pack. Trace one kit backwards to its component sources and forwards to a customer shipment. Establish who issues the adverse-event or field action notice if one component is implicated 2 23 3.

If a variant needs a different package, contact duration or release process, treat it as a separate row for regulatory and supplier verification. Verify VEMERIX product information as the manufacturer's own information 28. That information can help identify models to shortlist. Purchase acceptance depends on the candidate model's evidence for the chosen destination and lot.

6. Coordinate catalogue and OEM orders through dated decisions

A 14-day document review is an illustrative coordination window for an existing validated product where the seller and buyer agree on access and reviewers. Requesting the first packet within 72 hours or a rapid trace result can be negotiated. Late disclosure calls for a dated clarification or purchasing hold under the agreement. Assess validation and capability against the actual product and records. Where there is a new size, packaging combination or label, plan separate development and regulated change activity.

Catalogue transaction

During days 1–3, obtain the exact destination, catalogue model and packaging levels. QA verifies the list of evidence by production configuration. Regulatory Affairs checks current device status and identifiers, applicable decisions or exemptions and the label or IFU. Secure present records supporting legal manufacturer, site and responsibility. Provide the agreed sample and certificate access. If an identifier is not required in this scenario, record the basis. Decide which records must accompany all later shipments and which can be referenced against an approved design revision 5 6 8 10 13 16.

During days 4–7, verify package and sterilization coverage. Use the documented route, current validation and approved inspection methods. Aged packaging results and transit simulation answer different questions. Verify the edition and scope the supplier applies. Check whether validation, requalification or a controlled change needs additional work for this order. Use the intended population, exposure and label for any assessment of residuals; check continued applicability of existing evidence separately from the publication of a new standard 17 18 19 20 21.

During days 8–10, confirm what trace links the sample pack to the finished lot, incoming components and approved release. For a kit, pick one high-consequence sub-tier part and confirm whether its packaging and lot can be matched to the final unit and shipment. Assign a contact for safety complaints and confirm roles for any applicable reporting duties. Rehearse retrieval under the agreed internal time and map external paths separately. A successful test provides evidence of the recorded lot and controls exercised 2 3 4 22 23 24.

During days 11–14, hold a commercial authorization meeting. Attach the verified catalogue specification and the unissued production-lot evidence list. Confirm pricing inputs and tariff review with the importer. Agree the planned source of each release document and the schedules for manufacturing, inspection and shipping. Price the actual samples for each size and test purpose and label what is retained. Sign the order when buyer's qualification terms are met, with acceptance and production-lot release documented for the final shipment. A lot-specific process packet may be due later in the manufacturing schedule; it must match the delivered lots before they enter clinical stock.

Development or private-label transaction

For a novel variant, the appropriate initial approval might be limited to a development estimate, prototype or tooling. Use a document identifying one covered variant and sample purpose. Define which changes need approved drawings, validation extension, notified body or regulator involvement, or a separate filing. Determine who holds the production design and who can release the claimed version. Laboratory records can exist before the final market label, but sample evidence must cover the agreed questions. A prototype bearing a concept identifier or provisional label can be acceptable for a controlled bench review. Attach that restriction to the custody and disposal record 4 5 11.

At production approval, do an authorized design and market review on the exact offered model and package. Commercial development may still face a substantive validation dependency. For example, a larger model could exceed the range the packaging validation actually assessed. Before clinical shipment, the manufacturer and the responsible quality and regulatory teams must resolve the validation gap for that model and pack. Require a replacement or applicable approved evidence where needed. Keep any sample released for engineering evaluation out of clinical distribution. If proposed design changes remain open, price the cost of continuing work and the consequence if they cannot reach the agreed market scope. No manufacturing milestone by itself establishes either lot release or the lawful first shipment 4 5 17.

7. Evidence and version control

Regulator portals are used to locate records for specific products. Individual FDA examples Z-1824-2026 and Z-2546-2026 illustrate different verification questions about the actual lot and affected item. No record sample is used here to estimate comparative supplier quality. For China use the register and applicable decree. For EU and U.S. decisions, confirm the named instrument against the exact device and date. The prices are hypothetical, with scope and denominator shown. Check the legal tariff terms using the actual destination, entry, article and importer classification 2 5 8 10 11 7 25.

The standards sources describe editions and public scope. Use the applicable purchased text, authoritative recognition or market status record and approved quality records for clause-level acceptance. The sampling example can use an agreed plan distinct from ISO 2859-1:2026. Check edition, adoption and legitimate transition if the supplier or buyer uses another approved method and review existing product validation evidence against the confirmed basis. Consider the applicable population and duration of use for EO residual evidence. For aging and sterile barrier matters use the actual shipping and packaging evidence and applicable validated specifications 4 17 18 19 20 21 27.

8. Close the order with a traceable acceptance decision

A completed discrepancy-to-release example

Assume a qualified distributor orders two catalogue configurations, size S and size L, for one named EEA destination. The approved order expects 3,000 sellable S units and 2,000 sellable L units. Each sterile unit carton and outer case are already documented with the applicable label revision and identifiers. For this example the purchase team agreed that each SKU has one identifiable homogeneous lot, and that no units consumed for testing or held separately as retains are counted as sellable. Both variants passed qualification under the exact declaration, applicable certificate, label and agreed market determination. This is a hypothetical demonstration of staged documentary decisions 4 5 13.

At pre-shipment reconciliation, the manufacturer’s lot release record identifies two loads. The packing export references the correct S lot and labels but incorrectly assigns one L pallet to the S record. The buyer stops release of the disputed pallet and prevents it entering the sellable stock count, retaining the original packing export and pack photographs. Ask manufacturer QA to identify whether the issue is a clerical discrepancy limited to the export, a packaging mix-up or a missing validated release. Trace each affected carton to original manufacturer lot and sterilization load; then review the independent quantity, position and physical identifier checks. The importer and Regulatory Affairs review whether product labels and relevant document scope still match and whether any corrective action or notification is due. Have commercial staff confirm application of hold and payment terms separately.

Suppose the manufacturer confirms from the packing log, approved release and carton check that 50 L packs were correctly labelled but associated with the wrong electronic shipping record. The old record can be superseded under controlled correction. Retest pack scans, quantities and lot references against the revised export, retaining old and new records and authorized rationale. If the package label itself was wrong, a paperwork correction is insufficient. Hold affected products for determination by manufacturer QA and Regulatory Affairs, for authorized rework if appropriate or rejection, then follow the approved procedure. If no applicable lot release can be evidenced, hold the affected products outside clinical distribution and use the contract remedy. A small sample acceptance result is evidence for its own test and cannot substitute for the missing controlled release.

For a separate destructive and retention allowance, assume the approved hypothetical plan needs eight units of each size for a validated functional test, three per size for a different destructive package test, and five unopened per size for reference retention. These duties request 16, six and ten units, respectively, or 32 units in addition to the 5,000 sellable count. Units drawn for ordinary non-destructive observations return to stock only under the agreed protocol and with package integrity preserved. Record that both defined lots were represented, availability under each SKU and where each unit was kept or destroyed. This is an example allocation under an agreed plan and is not a sample-size recommendation or substitute for the applicable standard or validated product sampling requirements 17 18 27.

In the resolved branch, manufacturer QA signs the corrected export and links all 50 disputed L units to their original, documented lot release. The authorized buyer independently matches the revised electronic record to carton and case identifiers. Receiving verifies that both accepted lots and all cartons match the contract and that there is no new discrepancy on arrival. The temporary hold on the 50 L units ends after the documented combination of QA disposition, Regulatory Affairs confirmation and independent receiving checks. The release includes 3,000 S and 2,000 L for sale, with zero sellable units still held. The 11 tested S and 11 tested L units were consumed under the approved plan and appear in the disposition log as destroyed after testing. The five unopened S and five unopened L retains are segregated in the designated retention stock, with controlled access and references to their respective lots. The receiving record thus accounts for all 3,016 S and 2,016 L units 4 5 27.

Assume the agreed unit price is EUR 18 for S and EUR 20 for L, the retain and test allowance is included in those rates, and taxes, freight and fees are settled separately. The sellable order totals EUR 94,000. Under an assumed 30% deposit and 70% balance payable upon complete acceptance in the named warehouse, EUR 28,200 was paid and EUR 65,800 was pending during the pre-shipment hold. The balance becomes payable once authorized receiving has completed and recorded acceptance of both lots. The corrected packing export alone does not trigger that obligation. The final record identifies the exact accepted models, lots, counts, evidence and approval date for the clinical inventory transfer and attaches the receiving and QA sign-offs to the Finance instruction. A buyer using a VEMERIX or another supplier catalogue can request the device- and market-specific documents needed to support this type of decision 4 5 28.

Sources

  1. FDA openFDA. Device recall database scope, definitions and limits.
  2. U.S. FDA individual recall record Z-1824-2026, Centurion Circumcision Kit, including exact package identifiers, affected lot and stated reason.
  3. U.S. FDA Total Product Life Cycle entry, OHG circumcision tray, with references to convenience-kit regulatory guidance and named recalls.
  4. International Organization for Standardization (ISO), ISO 13485:2016 — Medical devices — Quality management systems — Requirements for regulatory purposes (Clauses 7.5.9 Traceability and 8.2.2 Complaint handling).
  5. European Parliament and Council, Regulation (EU) 2017/745 of 5 April 2017 on medical devices (EU MDR) (Articles 10, 13, 14, 27, 87; Annex IV, Annex VI, Annex IX, Annex XII).
  6. U.S. Food and Drug Administration (FDA), Establishment Registration and Device Listing for Manufacturers and Initial Importers of Devices (21 CFR Part 807, including 21 CFR 807.39 misbranding prohibition).
  7. U.S. FDA individual recall record Z-2546-2026, Medline convenience kits, affected models, lot identifiers, components and instructions.
  8. China NMPA. Domestic medical device registration search; retrieve the offered device registration by exact certificate number and confirm scope and current status.
  9. U.S. FDA. Product Classification, OHG circumcision tray; jurisdiction-specific regulatory consideration for convenience kits.
  10. FDA 510(k) premarket notification database. Verify the exact device, applicant and indication in the decision records.
  11. State Council of China. Regulations on Supervision and Administration of Medical Devices, Order 739, Articles 13–14, 22 and 30–32.
  12. U.S. Food and Drug Administration (FDA), General and Plastic Surgery Devices: Reclassification of Certain Surgical Staplers (Final Order, 86 FR 56195, 21 CFR 878.4740).
  13. Medical Device Coordination Group. Guidance on Basic UDI-DI and changes to UDI-DI, MDCG 2018-1 Rev. 4.
  14. European Commission. EUDAMED UDI/Devices registration and mandatory-use implementation.
  15. European Parliament and Council, Regulation (EU) 2023/607 of 15 March 2023 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices.
  16. U.S. Food and Drug Administration (FDA), Unique Device Identification System (21 CFR Part 830, including 21 CFR 830.50 changes requiring a new Device Identifier) and Global Unique Device Identification Database (GUDID).
  17. ISO 11607-1:2019. Packaging for terminally sterilized devices, Part 1, materials, sterile barrier and packaging systems; see edition and amendments.
  18. ISO 11607-2:2019. Packaging for terminally sterilized devices, Part 2, validation requirements for forming, sealing and assembly processes.
  19. FDA. Recognition 14-575, ASTM F1980-21, Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices.
  20. International Organization for Standardization (ISO), ISO 11135:2014+Amd 1:2018 — Sterilization of health-care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices (with ISO 11737-1 bioburden determination).
  21. ISO 10993-7:2026, Biological evaluation of medical devices, Ethylene oxide sterilization residuals.
  22. U.S. Food and Drug Administration (FDA), Medical Devices; Quality System Regulation Amendments (Quality Management System Regulation — QMSR Final Rule, 89 FR 7496, 21 CFR Part 820 & 21 CFR 820.35(a), effective February 2, 2026).
  23. FDA. Mandatory reporting requirements for device manufacturers, importers and device user facilities.
  24. World Health Organization. Overview of the WHO prequalification of male circumcision devices assessment, including post-qualification responsibilities (2019).
  25. U.S. International Trade Commission. Harmonized Tariff Schedule of the United States, current table and relevant chapter notes.
  26. USTR. Section 301 tariff actions and product exclusions, for checking applicable entry-date instruments alongside HTSUS Chapter 99.
  27. ISO 2859-1:2026. Sampling procedures for inspection by attributes, Part 1, lot-by-lot sampling schemes indexed by acceptance quality limit.
  28. VEMERIX (Weihai Medison Medical Equipment Co., Ltd.), Corporate Overview, Quality System, and Surgical Solutions Portfolio.

Talk to VEMERIX

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care.